Label: LAMISIL- terbinafine
hydrochloride tablet
- NDC Code(s): 0078-0179-05, 0078-0179-15
- Packager: Novartis Pharmaceuticals Corporation
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Drug Label Information
Updated February 2, 2015
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Print Drug Label Info
- HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LAMISIL Tablets safely and effectively.
See full prescribing information for LAMISIL Tablets.
LAMISIL® (terbinafine hydrochloride) Tablets, 250 mg For oral use
Initial U.S. Approval: 1992INDICATIONS AND USAGE
Lamisil Tablets are an allylamine antifungal indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium) (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
Tablet, 250 mg (3)
CONTRAINDICATIONS
Lamisil Tablets are contraindicated in individuals with a history of allergic reaction to oral terbinafine because of the risk of anaphylaxis. (4)
WARNINGS AND PRECAUTIONS
- Liver failure, sometimes leading to liver transplant or death,
has occurred with the use of oral terbinafine. Obtain pretreatment
serum transaminases. Discontinue Lamisil Tablets if liver injury
develops. (5.1, 5.8)
- Taste disturbance, including taste loss, has been reported with
the use of Lamisil Tablets. Taste disturbance can be severe, may be
prolonged, or may be permanent. Discontinue Lamisil Tablets if
taste disturbance occurs. (5.2)
- Smell disturbance, including loss of smell, has been reported
with the use of Lamisil Tablets. Smell disturbance may be
prolonged, or may be permanent. Discontinue Lamisil Tablets if
smell disturbance occurs. (5.3)
- Depressive symptoms have been reported with terbinafine use.
Prescribers should be alert to the development of depressive
symptoms. (5.4)
- Severe neutropenia has been reported. If the neutrophil count
is <1000 cells/mm3, Lamisil Tablets should be discontinued. (5.5)
- Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with oral terbinafine use. If signs or symptoms of drug reaction occur, treatment with Lamisil Tablets should be discontinued. (5.6)
ADVERSE REACTIONS
Common (>2% of patients treated with Lamisil Tablets) reported adverse events include headache, diarrhea, rash, dyspepsia, liver enzyme abnormalities, pruritus, taste disturbance, nausea, abdominal pain, and flatulence. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.DRUG INTERACTIONS
Terbinafine is an inhibitor of CYP450 2D6 isozyme and has an effect on metabolism of desipramine. Drug interactions have also been noted with cimetidine, fluconazole, cyclosporine, rifampin, and caffeine. (7.1)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 2/2015
Close - Liver failure, sometimes leading to liver transplant or death,
has occurred with the use of oral terbinafine. Obtain pretreatment
serum transaminases. Discontinue Lamisil Tablets if liver injury
develops. (5.1, 5.8)
- FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hepatotoxicity
5.2 Taste Disturbance Including Loss of Taste
5.3 Smell Disturbance Including Loss of Smell
5.4 Depressive Symptoms
5.5 Hematologic Effects
5.6 Serious Skin/Hypersensitivity Reactions
5.7 Lupus Erythematosus
5.8 Laboratory Monitoring
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
7.1 Drug-Drug Interactions
7.2 Food Interactions
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
12.4 Microbiology
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
- *
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE
Lamisil (terbinafine hydrochloride) Tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).
Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.
Close - 2 DOSAGE AND ADMINISTRATION
Fingernail onychomycosis: One 250 mg tablet once daily for 6 weeks.
Toenail onychomycosis: One 250 mg tablet once daily for 12 weeks.
The optimal clinical effect is seen some months after mycological cure and cessation of treatment. This is related to the period required for outgrowth of healthy nail.
Close - 3 DOSAGE FORMS AND STRENGTHS
Tablet, 250 mg white to yellow-tinged white circular, bi-convex, beveled tablets imprinted with “LAMISIL” in circular form on one side and code “250” on the other side.
Close - 4 CONTRAINDICATIONS
Lamisil Tablets are contraindicated in individuals with a history of allergic reaction to oral terbinafine because of the risk of anaphylaxis.
Close - 5 WARNINGS AND PRECAUTIONS
5.1 Hepatotoxicity
Cases of liver failure, some leading to liver transplant or death, have occurred with the use of Lamisil Tablets in individuals with and without preexisting liver disease.
In the majority of liver cases reported in association with use of Lamisil Tablets, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease. Treatment with Lamisil Tablets should be discontinued if biochemical or clinical evidence of liver injury develops.
Lamisil Tablets are not recommended for patients with chronic or active liver disease. Before prescribing Lamisil Tablets, liver function tests should be performed since hepatotoxicity may occur in patients with and without pre-existing liver disease. Periodic monitoring of liver function tests is recommended. Lamisil should be immediately discontinued in case of elevation of liver function tests. Patients prescribed Lamisil Tablets should be warned to report immediately to their physician any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine, or pale stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’s liver function should be immediately evaluated.
5.2 Taste Disturbance Including Loss of Taste
Taste disturbance, including taste loss, has been reported with the use of Lamisil Tablets. It can be severe enough to result in decreased food intake, weight loss, anxiety, and depressive symptoms. Taste disturbance may resolve within several weeks after discontinuation of treatment, but may be prolonged (greater than 1 year), or may be permanent. If symptoms of a taste disturbance occur, Lamisil Tablets should be discontinued.
5.3 Smell Disturbance Including Loss of Smell
Smell disturbance, including loss of smell, has been reported with the use of Lamisil Tablets. Smell disturbance may resolve after discontinuation of treatment, but may be prolonged (greater than 1 year), or may be permanent. If symptoms of a smell disturbance occur, Lamisil Tablets should be discontinued.
5.4 Depressive Symptoms
Depressive symptoms have occurred during postmarketing use of Lamisil Tablets. Prescribers should be alert to the development of depressive symptoms, and patients should be instructed to report depressive symptoms to their physician.
5.5 Hematologic Effects
Transient decreases in absolute lymphocyte counts (ALCs) have been observed in controlled clinical trials. In placebo-controlled trials, 8/465 subjects receiving Lamisil Tablets (1.7%) and 3/137 subjects receiving placebo (2.2%) had decreases in ALC to below 1000/mm3 on 2 or more occasions. In patients with known or suspected immunodeficiency, physicians should consider monitoring complete blood counts if treatment continues for more than 6 weeks. Cases of severe neutropenia have been reported. These were reversible upon discontinuation of Lamisil Tablets, with or without supportive therapy. If clinical signs and symptoms suggestive of secondary infection occur, a complete blood count should be obtained. If the neutrophil count is ≤1000 cells/mm3, Lamisil Tablets should be discontinued and supportive management started.
5.6 Serious Skin/Hypersensitivity Reactions
There have been postmarketing reports of serious skin/hypersensitivity reactions [e.g., Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome]. Manifestations of DRESS syndrome may include cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more organ complications such as hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. If progressive skin rash or signs/symptoms of the above drug reactions occur, treatment with Lamisil Tablets should be discontinued.
5.7 Lupus Erythematosus
During postmarketing experience, precipitation and exacerbation of cutaneous and systemic lupus erythematosus have been reported in patients taking Lamisil Tablets. Lamisil Tablets should be discontinued in patients with clinical signs and symptoms suggestive of lupus erythematosus.
Close5.8 Laboratory Monitoring
Measurement of serum transaminases (ALT and AST) is advised for all patients before taking Lamisil Tablets.
- 6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most frequently reported adverse events observed in the 3 US/Canadian placebo-controlled trials are listed in the table below. The adverse events reported encompass gastrointestinal symptoms (including diarrhea, dyspepsia, and abdominal pain), liver test abnormalities, rashes, urticaria, pruritus, and taste disturbances. Changes in the ocular lens and retina have been reported following the use of Lamisil Tablets in controlled trials. The clinical significance of these changes is unknown. In general, the adverse events were mild, transient, and did not lead to discontinuation from study participation.
- *
- Liver enzyme abnormalities ≥2x the upper limit of normal range.
Adverse Event Discontinuation Lamisil Tablets Placebo Lamisil Tablets Placebo (%) (%) (%) (%) n=465 n=137 n=465 n=137 Headache 12.9 9.5 0.2 0.0 Gastrointestinal Symptoms: Diarrhea 5.6 2.9 0.6 0.0 Dyspepsia 4.3 2.9 0.4 0.0 Abdominal Pain 2.4 1.5 0.4 0.0 Nausea 2.6 2.9 0.2 0.0 Flatulence 2.2 2.2 0.0 0.0 Dermatological Symptoms: Rash 5.6 2.2 0.9 0.7 Pruritus 2.8 1.5 0.2 0.0 Urticaria 1.1 0.0 0.0 0.0 Liver Enzyme Abnormalities* 3.3 1.4 0.2 0.0 Taste Disturbance 2.8 0.7 0.2 0.0 Visual Disturbance 1.1 1.5 0.9 0.0 Close6.2 Postmarketing Experience
The following adverse events have been identified during postapproval use of Lamisil Tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders: Pancytopenia, agranulocytosis, severe neutropenia, thrombocytopenia, anemia [see Warnings and Precautions (5.5)]
Immune system disorders: Serious hypersensitivity reactions e.g., angioedema and allergic reactions (including anaphylaxis), precipitation and exacerbation of cutaneous and systemic lupus erythematosus [see Warnings and Precautions (5.7)], serum sickness-like reaction
Psychiatric disorders: Anxiety and depressive symptoms independent of taste disturbance have been reported with use of Lamisil Tablets. In some cases, depressive symptoms have been reported to subside with discontinuance of therapy and to recur with reinstitution of therapy [see Warnings and Precautions (5.4)].
Nervous system disorders: Cases of taste disturbance, including taste loss, have been reported with the use of Lamisil Tablets. It can be severe enough to result in decreased food intake, weight loss, anxiety, and depressive symptoms. Cases of smell disturbance, including smell loss, have been reported with the use of Lamisil Tablets [see Warnings and Precautions (5.2, 5.3)]. Cases of paresthesia and hypoesthesia have been reported with the use of Lamisil Tablets.
Eye disorders: Visual field defects, reduced visual acuity
Ear and labyrinth disorders: Hearing impairment, vertigo, tinnitus
Vascular disorders: Vasculitis
Gastrointestinal disorders: Pancreatitis, vomiting
Hepatobiliary disorders: Cases of liver failure some leading to liver transplant or death [see Warnings and Precautions (5.1)], idiosyncratic and symptomatic hepatic injury. Cases of hepatitis, cholestasis, and increased hepatic enzymes [see Warnings and Precautions (5.1)] have been seen with the use of Lamisil Tablets.
Skin and subcutaneous tissue disorders: Serious skin reactions [e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, bullous dermatitis, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome] [see Warnings and Precautions (5.6)], acute generalized exanthematous pustulosis, psoriasiform eruptions or exacerbation of psoriasis, photosensitivity reactions, hair loss
Musculoskeletal and connective tissue disorders: Rhabdomyolysis, arthralgia, myalgia
General disorders and administration site conditions: Malaise, fatigue, influenza-like illness, pyrexia
Investigations: Altered prothrombin time (prolongation and reduction) in patients concomitantly treated with warfarin and increased blood creatine phosphokinase have been reported
- 7 DRUG INTERACTIONS
7.1 Drug-Drug Interactions
In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme. Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of Lamisil Tablets should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug. In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increase in area under the curve (AUC). In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of Lamisil Tablets. In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/dextrorphan metabolite ratio in urine by 16- to 97-fold on average. Thus, terbinafine may convert extensive CYP2D6 metabolizers to poor metabolizer status.
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin. In vivo drug-drug interaction studies conducted in healthy volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. Terbinafine decreases the clearance of caffeine by 19%. Terbinafine increases the clearance of cyclosporine by 15%.
The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant.
Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine Cmax and AUC, respectively. Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (Cmax and AUC) of terbinafine when concomitantly administered.
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between Lamisil Tablets and these changes has not been established.
Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. Terbinafine clearance is unaffected by cyclosporine. There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers.
Close7.2 Food Interactions
An evaluation of the effect of food on Lamisil Tablets was conducted. An increase of less than 20% of the AUC of terbinafine was observed when Lamisil Tablets were administered with food. Lamisil Tablets can be taken with or without food.
- 8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category B
There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that Lamisil Tablets not be initiated during pregnancy.
Oral reproduction studies have been performed in rabbits and rats at doses up to 300 mg/kg/day [12x to 23x the maximum recommended human dose (MRHD), in rabbits and rats, respectively, based on body surface area (BSA) comparisons] and have revealed no evidence of impaired fertility or harm to the fetus due to terbinafine.
8.3 Nursing Mothers
After oral administration, terbinafine is present in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:1. Treatment with Lamisil Tablets is not recommended in women who are nursing.
8.4 Pediatric Use
The safety and efficacy of Lamisil Tablets have not been established in pediatric patients with onychomycosis.
8.5 Geriatric Use
Clinical studies of Lamisil Tablets did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Close8.6 Renal Impairment
In patients with renal impairment (creatinine clearance less than or equal to 50 mL/min) the use of Lamisil Tablets has not been adequately studied.
- 10 OVERDOSAGE
Clinical experience regarding overdose with oral terbinafine is limited. Doses up to 5 grams (20 times the therapeutic daily dose) have been taken without inducing serious adverse reactions. The symptoms of overdose included nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, and headache.
Close - 11 DESCRIPTION
Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.
Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26CIN with a molecular weight of 327.90, and the following structural formula:
Terbinafine hydrochloride is a white to off-white fine crystalline powder. It is freely soluble in methanol and methylene chloride, soluble in ethanol, and slightly soluble in water.
Each tablet contains:
Active Ingredients: terbinafine hydrochloride (equivalent to 250 mg base)
Inactive Ingredients: colloidal silicon dioxide NF, hydroxypropyl methylcellulose USP, magnesium stearate NF, microcrystalline cellulose NF, and sodium starch glycolate NF.
Close - 12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Terbinafine is an allylamine antifungal [see Clinical Pharmacology (12.4)].
12.3 Pharmacokinetics
Following oral administration, terbinafine is well absorbed (>70%) and the bioavailability of Lamisil Tablets as a result of first-pass metabolism is approximately 40%. Peak plasma concentrations of 1 µg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 µg.h/mL. An increase in the AUC of terbinafine of less than 20% is observed when Lamisil Tablets are administered with food.
In plasma, terbinafine is >99% bound to plasma proteins and there are no specific binding sites. At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours. Terbinafine is distributed to the sebum and skin. A terminal half-life of 200-400 hours may represent the slow elimination of terbinafine from tissues such as skin and adipose. Prior to excretion, terbinafine is extensively metabolized by at least 7 CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19. No metabolites have been identified that have antifungal activity similar to terbinafine. Approximately 70% of the administered dose is eliminated in the urine.
In patients with renal impairment (creatinine clearance <50 mL/min) or hepatic cirrhosis, the clearance of terbinafine is decreased by approximately 50% compared to normal volunteers. No effect of gender on the blood levels of terbinafine was detected in clinical trials. No clinically relevant age-dependent changes in steady-state plasma concentrations of terbinafine have been reported.
Close12.4 Microbiology
Terbinafine, an allylamine antifungal, inhibits biosynthesis of ergosterol, an essential component of fungal cell membrane, via inhibition of squalene epoxidase enzyme. This results in fungal cell death primarily due to the increased membrane permeability mediated by the accumulation of high concentrations of squalene but not due to ergosterol deficiency. Depending on the concentration of the drug and the fungal species test in vitro, terbinafine hydrochloride may be fungicidal. However, the clinical significance of in vitro data is unknown.
Terbinafine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections:
Trichophyton mentagrophytes
Trichophyton rubrum
The following in vitro data are available, but their clinical significance is unknown. In vitro, terbinafine exhibits satisfactory MIC’s against most strains of the following microorganisms; however, the safety and efficacy of terbinafine in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials:
Candida albicans
Epidermophyton floccosum
Scopulariopsis brevicaulis
- 13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In a 28-month oral carcinogenicity study in rats, an increase in the incidence of liver tumors was observed in males at the highest dose tested, 69 mg/kg/day (2x the MRHD based on AUC comparisons of the parent terbinafine); however, even though dose-limiting toxicity was not achieved at the highest tested dose, higher doses were not tested.
The results of a variety of in vitro (mutations in E. coli and S. typhimurium, DNA repair in rat hepatocytes, mutagenicity in Chinese hamster fibroblasts, chromosome aberration, and sister chromatid exchanges in Chinese hamster lung cells), and in vivo (chromosome aberration in Chinese hamsters, micronucleus test in mice) genotoxicity tests gave no evidence of a mutagenic or clastogenic potential.
Oral reproduction studies in rats at doses up to 300 mg/kg/day (approximately 12x the MRHD based on BSA comparisons) did not reveal any specific effects on fertility or other reproductive parameters. Intravaginal application of terbinafine hydrochloride at 150 mg/day in pregnant rabbits did not increase the incidence of abortions or premature deliveries nor affect fetal parameters.
Close13.2 Animal Toxicology and/or Pharmacology
A wide range of in vivo studies in mice, rats, dogs, and monkeys, and in vitro studies using rat, monkey, and human hepatocytes suggest that peroxisome proliferation in the liver is a rat-specific finding. However, other effects, including increased liver weights and APTT, occurred in dogs and monkeys at doses giving Css trough levels of the parent terbinafine 2-3x those seen in humans at the MRHD. Higher doses were not tested.
- 14 CLINICAL STUDIES
The efficacy of Lamisil Tablets in the treatment of onychomycosis is illustrated by the response of subjects with toenail and/or fingernail infections who participated in 3 US/Canadian placebo-controlled clinical trials.
Results of the first toenail trial, as assessed at week 48 (12 weeks of treatment with 36 weeks follow-up after completion of therapy), demonstrated mycological cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 70% of subjects. Fifty-nine percent (59%) of subjects experienced effective treatment (mycological cure plus 0% nail involvement or >5mm of new unaffected nail growth); 38% of subjects demonstrated mycological cure plus clinical cure (0% nail involvement).
In a second toenail trial of dermatophytic onychomycosis, in which nondermatophytes were also cultured, similar efficacy against the dermatophytes was demonstrated. The pathogenic role of the nondermatophytes cultured in the presence of dermatophytic onychomycosis has not been established. The clinical significance of this association is unknown.
Results of the fingernail trial, as assessed at week 24 (6 weeks of treatment with 18 weeks follow-up after completion of therapy), demonstrated mycological cure in 79% of subjects, effective treatment in 75% of the subjects, and mycological cure plus clinical cure in 59% of the subjects.
The mean time to overall success was approximately 10 months for the first toenail trial and 4 months for the fingernail trial. In the first toenail trial, for subjects evaluated at least 6 months after achieving clinical cure and at least 1 year after completing therapy with Lamisil Tablets, the clinical relapse rate was approximately 15%.
Close - 16 HOW SUPPLIED/STORAGE AND HANDLING
Lamisil Tablets are supplied as white to yellow-tinged white circular, bi-convex, beveled tablets containing 250 mg of terbinafine imprinted with “LAMISIL” in circular form on one side and code “250” on the other.
Bottles of 100 tablets NDC 0078-0179-05
Bottles of 30 tablets NDC 0078-0179-15
Store Lamisil Tablets below 25°C (77°F); in a tight container. Protect from light.
Close - 17 PATIENT COUNSELING INFORMATION
See FDA-Approved Patient Labeling (Patient Information)
Patients taking Lamisil Tablets should receive the following information and instructions:
- Advise patients to immediately report to their physician or get emergency help if they experience any of the following symptoms: hives, mouth sores, blistering and peeling of skin, swelling of face, lips, tongue, or throat, difficulty swallowing or breathing. Lamisil Tablets treatment should be discontinued.
- Advise patients to immediately report to their physician any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools. Lamisil Tablets treatment should be discontinued.
- Advise patients to report to their physician any signs of taste disturbance, smell disturbance and/or depressive symptoms, fever, skin eruption, lymph node enlargement, erythema, scaling, loss of pigment, and unusual photosensitivity that can result in a rash. Lamisil Tablets treatment should be discontinued.
- Advise patients to minimize exposure to natural and artificial sunlight (tanning beds or UVA/B treatment) while using Lamisil Tablets.
- Advise patients that if they forget to take Lamisil Tablets, to take their tablets as soon as they remember, unless it is less than 4 hours before the next dose is due. Advise patients to call their physician if they take too many Lamisil Tablets.
T2015-13
Close
February 2015 - PATIENT PACKAGE INSERT
Patient Information
Lamisil (Lam-i-sil)
(terbinafine hydrochloride)
Tablets
What are Lamisil Tablets?
Lamisil Tablets is a prescription antifungal medicine used to treat fungal infections of the fingernails and toenails (onychomycosis).
Your doctor should do tests to check you for fungal infection of your nails before you start Lamisil Tablets.
It is not known if Lamisil Tablets are safe and effective in children for the treatment of onychomycosis.
Who should not take Lamisil Tablets?
Do not take Lamisil Tablets if you are allergic to terbinafine hydrochloride when taken by mouth.
What should I tell my doctor before taking Lamisil Tablets?
Before you take Lamisil Tablets, tell your doctor if you:
- have or had liver problems
- have a weakened immune system (immunocompromised)
- have lupus (an autoimmune disease)
- have any other medical conditions
- are pregnant or plan to become pregnant. It is not known if Lamisil Tablets will harm your unborn baby. You should not start taking Lamisil Tablets during pregnancy without talking with your doctor.
- are breastfeeding or plan to breastfeed. Lamisil can pass into your breast milk and may harm your baby. Talk to your doctor about the best way to feed your baby if you take Lamisil Tablets.
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Lamisil Tablets may affect the way other medicines work and other medicines may affect how Lamisil Tablets work. Especially tell your doctor if you take:
- a medicine for depression
- a medicine for high blood pressure
- a medicine for heart problems
- desipramine (Norpramin)
- caffeine
- cyclosporine (Gengraf, Neoral, Sandimmune)
- fluconazole (Diflucan)
- rifampin (Rifater, Rifamate, Rimactane, Rifadine)
- cimetidine (Tagamet)
If you are not sure if your medicine is one listed above, ask your doctor or pharmacist.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
How should I take Lamisil Tablets?
- Take Lamisil Tablets exactly as your doctor tells you to take it.
- Lamisil comes as a tablet that you take by mouth.
- Lamisil Tablets are usually taken:
- 1 time each day for 6 weeks to treat fungal infections of your fingernail, or
- 1 time each day for 12 weeks to treat fungal infections of your toenail
- Lamisil Tablets can be taken with or without food.
- If you miss a dose of Lamisil Tablets, take it as soon as you remember. If it is less than 4 hours before your next dose, skip the missed dose. Just take the next dose at your regular time.
If you take too many Lamisil Tablets call your doctor. You may have the following symptoms:
- nausea
- vomiting
- stomach (abdomen) pain
- dizziness
- rash
- frequent urination
- headache
What should I avoid while taking Lamisil Tablets?
- Avoid sunlight. Lamisil Tablets can make your skin sensitive to the sun and the light from sunlamps and tanning beds. You can get a severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. Talk to your doctor if you get sunburn.
What are the possible side effects of Lamisil Tablets?
Lamisil Tablets may cause serious side effects, including:
- liver problems that can lead to the need for
liver transplant, or death. Tell your doctor right away if
you get any of these symptoms of a liver problem:
- nausea
- upper right stomach-area (abdomen) pain
- poor appetite
- yellowing of your skin or eyes (jaundice)
- tiredness
- dark (tea-colored) urine
- vomiting
- pale or light colored stools
Your doctor should do a blood test to check you for liver problems before you take Lamisil Tablets.
- change in taste or loss of taste may
happen with Lamisil Tablets and can be severe. This may improve
within several weeks after you stop taking Lamisil Tablets, but may
last for a long time or may become permanent. Tell your doctor if
you have:
- change in taste or loss of taste
- poor appetite
- unwanted weight loss
- anxiousness
- change in mood or depressive symptoms
- change in smell or loss of smell may happen with Lamisil Tablets. This may improve after you stop taking Lamisil Tablets, but may last for a long time or may become permanent.
- depressive symptoms. Tell your doctor right
away if you have any of these signs or symptoms:
- feel sad or worthless
- change in sleep pattern
- loss of energy or interest in daily activities
- restlessness
- mood changes
- low white blood cell count. People taking Lamisil Tablets may have a decrease in white blood cells, especially neutrophils. You may have a higher risk of getting an infection when your white blood cell count is low.
- serious skin or allergic reactions.
Tell your doctor right away or get emergency help if you get any of
these symptoms:
- skin rash, hives, sores in your mouth, or your skin blisters and peels
- swelling of your face, eyes, lips, tongue or throat, trouble swallowing or breathing
- drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome – skin rash, fever, swollen lymph glands, involvement of internal organs
- new or worsening lupus (an autoimmune
disease). Stop taking Lamisil Tablets and tell your doctor
if you get any of the following:
- progressive skin rash that is scaly, red, shows scarring, or loss of pigment
- unusual sensitivity to the sun that can lead to a rash
The most common side effects of Lamisil Tablets include:
- headache
- diarrhea
- rash
- upset stomach
- abnormal liver function tests
- itching
- change in taste
- nausea
- stomach-area (abdomen) pain
- gas
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of Lamisil Tablets. For information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store Lamisil Tablets?
- Store Lamisil Tablets below 77°F (25°C)
- Keep Lamisil Tablets in a tightly closed container and keep out of the light.
Keep Lamisil Tablets and all medicines out of the reach of children.
General information about the safe and effective use of Lamisil Tablets.
Medicines are sometimes prescribed for purposes other than those listed in Patient Information. Do not use Lamisil Tablets for a condition for which it was not prescribed. Do not give Lamisil Tablets to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or doctor for information about Lamisil Tablets that is written for health professionals.
What are the ingredients in Lamisil Tablets?
Active ingredient: terbinafine hydrochloride
Inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate
This Patient Information has been approved by the U.S. Food and Drug Administration.
Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936© Novartis
T2015-14
Close
February 2015 - PRINCIPAL DISPLAY PANEL
PRINCIPAL DISPLAY PANEL
Package Label – 250 mg Tablets
Rx Only NDC 0078-0179-15
LAMISIL® (terbinafine hydrochloride)
30 Tablets
250 mg
Tablets equivalent to 250 mg base
Close - INGREDIENTS AND APPEARANCE
LAMISIL
terbinafine hydrochloride tabletProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0078-0179 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TERBINAFINE HYDROCHLORIDE (UNII: 012C11ZU6G) (TERBINAFINE - UNII:G7RIW8S0XP) TERBINAFINE 250 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) HYPROMELLOSES (UNII: 3NXW29V3WO) MAGNESIUM STEARATE (UNII: 70097M6I30) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color YELLOW (whitish to yellow-tinged white) Score no score Shape ROUND (circular) Size 11mm Flavor Imprint Code LAMISIL;250 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0078-0179-05 100 in 1 BOTTLE 2 NDC:0078-0179-15 30 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA020539 05/10/1996 CloseLabeler - Novartis Pharmaceuticals Corporation (002147023)


MMA fighter, 26, dies after suffering brain injury during match
by Ryan GaydosAn amateur mixed martial arts fighter died after suffering a brain injury during a match in Britain on Saturday and police said they were investigating.
Saeideh Aletaha, 26, was injured during a fight at a Fast and Furious Fight Series match in Southhampton and was taken to the hospital shortly after, police said. She died Sunday, according to BBC.
JORGE MASVIDAL HOLDING OUT HOPE FOR CONOR MCGREGOR FIGHT BUT SAYS 'THAT DUDE DON'T WANT IT'
The company released a statement Monday on Aletaha’s death.
“All competitors get in prepared that they may be injured and this is something not expected to happen 99.9% of the time,” the statement said. “But, it can and in this we make the environment as safe as possible with pre and post medicals from a Doctor, and full medical cover [throughout] with Doctor, Paramedic and Ambulance on site alongside our experienced team of staff with numerous first aiders, safety is not something ever skimped on in any of our 19 shows and all matches are made equal.
“Thoughts of course go out to all family, friends and team mates, if anyone needs any support please come to us or your coaches.
UFC FIGHTER DEDICATES WIN TO MOTHER WHO IS BATTLING STAGE 4 BREAST CANCER
“Thank you to our team on the night who acted with utmost professionalism and carried their duties out above and beyond to react to the situation, and again we are here for any of you that needs it in this sad time.”
Exile Gym, where Aletaha trained, posted a tribute to her.
CLICK HERE FOR MORE SPORTS COVERAGE ON FOXNEWS.COM
“Saeideh Aletaha was a lovely character with a beautiful soul. Her dedication to the sport was 110% travelling miles every day just to train,” the gym wrote. “She found her place with us just a few months ago but has become apart [sic] of the family and will be sorely missed.”


| ID | ReceivedOn | TxnNumber | TypeReceipt | QtyReceived | receivedBy | supplier | purchaseOrder | product | |
|---|---|---|---|---|---|---|---|---|---|
| {{goodsReceivedAudit.id}} | {{goodsReceivedAudit.receivedOn | date:'medium'}} | {{goodsReceivedAudit.txnNumber}} | {{goodsReceivedAudit.typeReceipt}} | {{goodsReceivedAudit.qtyReceived}} | {{goodsReceivedAudit.receivedById}} | {{goodsReceivedAudit.supplierId}} | {{goodsReceivedAudit.purchaseOrderId}} | {{goodsReceivedAudit.productId}} |


PM Modi Speaks At Madison Square Garden: Highlights
NEW YORK: Prime Minister Narendra Modi, in a saffron jacket, got a full-house reception on Sunday at New York's Madison Square Garden, a venue that rock stars dream of packing with a sell-out audience. He thanked the crowd of about 18,000 Indian Americans who constantly chanted his name, for the rousing welcome.
Here are the highlights of his speech:
- Prime Minister Narendra Modi arrives at Madison Square Garden
- Kavita Krishnamurthy sings the national anthem
- Mr Modi begins his address with 'Bharat Mata ki Jai'
- My greetings to you on the occasion of Navratri. I am fortunate to have this opportunity to meet you on such an auspicious occasions
- India used to be known as a country of snakes and snake charmers
- It is only because of you (Indian-American community) that we have made such a huge progress
- If not for you all,there wouldn't have been an IT revolution
- You (Indian-American community) have earned a lot of respect in USA through skills and values
- Through your actions and values you have earned immense respect
- I visited Taiwan once and an interpreter said your country has been a land of snakes and snake charmers
- I said 'No, we have been vastly under-valued. Our ancestors used to play with snakes, we play with mouse.'
- Many of you didn't get a chance to vote, but when the results came, not one of you must have been sleeping
- Many of you were involved in the election process
- You may not have voted in 2014 but when results were coming in, you celebrated
- Today, I am here to thank you all
- You have a huge contribution in building India's image.
- Winning an election is not just about post or chair, it's a responsibility
- I haven't taken a 15-minute break since I took over.
- For the first time in 30 years, a party won a clear majority in India
- Even the opinion makers could not make an opinion
- You all have several expectations from India. Even the people of India are expecting a lot from our government.
- We will be successful in fulfilling the aspirations of people
- The world is convinced that 21st century belongs to Asia
- We are a youthful nation with a very old culture. 65 per cent of Indians are below the age of 35.
- There is no reason to be disappointed. India will progress very fast and the skills of our youth will take the country ahead.
- When 125 crore people give their blessings, it automatically becomes God's blessing.
- We have three powers that nobody else has, and it is our duty to identify these powers, present it to the World and mobilise it:
Democracy - This is our biggest strength. Even the poorest man went out in the heat to hear speeches
Demographic dividend - 65% of people less than the age of 35 years
Demand - The World is looking at India
- Democracy is India's biggest strength
- Mahatma Gandhi made the freedom struggle a mass movement. Every Indian felt that yes, I am also a part of the freedom struggle. We want to make development a mass movement.
- The world needs teachers, we will supply teachers
- Mahatma Gandhi was an expatriate who returned to India. It will be 100 years of that event next year. Pravasi Bahartiya Divas will be held in Ahmedabad this time
- Those who stay in India for a long time had to report to police stations. They will not have to do so.


|
||||||||||
| PREV NEXT | FRAMES NO FRAMES |
| Packages that use Partition | |
|---|---|
| synoptic.algorithms.bisim | Provides for implementations of a coarsening and an refinement algorithm. |
| synoptic.algorithms.graph | Provides for algorithms on graphs. |
| synoptic.gui | Provides a simple GUI. |
| synoptic.model | Provides basic data structures, such as graphs, transitions, and events. |
| synoptic.model.interfaces |
| Uses of Partition in synoptic.algorithms.bisim |
|---|
| Methods in synoptic.algorithms.bisim with parameters of type Partition | |
|---|---|
static boolean |
Bisimulation.tryAndRecordSplitOp(ITemporalInvariant inv,
PartitionGraph pGraph,
java.util.HashMap<Partition,PartitionMultiSplit> splitsToDoByPartition,
Partition partitionBeingSplit,
PartitionMultiSplit splitOp)
Attempts to perform the splitOp on the pGraph to see whether or not the resulting graph has no other counter-examples for the invariant inv (i.e. |
| Method parameters in synoptic.algorithms.bisim with type arguments of type Partition | |
|---|---|
private static java.util.List<PartitionSplit> |
Bisimulation.getSplits(RelationPath<Partition> counterexampleTrace,
PartitionGraph pGraph)
Compute possible splits to remove the path counterexampleTrace from pGraph. |
static int |
Bisimulation.performOneSplitPartitionsStep(int numSplitSteps,
PartitionGraph pGraph,
java.util.List<RelationPath<Partition>> counterExampleTraces)
|
private static IOperation |
Bisimulation.tryAndRecordCandidateSplits(java.util.List<RelationPath<Partition>> counterexampleTraces,
PartitionGraph pGraph,
java.util.HashMap<Partition,PartitionMultiSplit> splitsToDoByPartition,
java.util.Set<ITemporalInvariant> newlySatisfiedInvariants)
|
private static IOperation |
Bisimulation.tryAndRecordCandidateSplits(java.util.List<RelationPath<Partition>> counterexampleTraces,
PartitionGraph pGraph,
java.util.HashMap<Partition,PartitionMultiSplit> splitsToDoByPartition,
java.util.Set<ITemporalInvariant> newlySatisfiedInvariants)
|
static boolean |
Bisimulation.tryAndRecordSplitOp(ITemporalInvariant inv,
PartitionGraph pGraph,
java.util.HashMap<Partition,PartitionMultiSplit> splitsToDoByPartition,
Partition partitionBeingSplit,
PartitionMultiSplit splitOp)
Attempts to perform the splitOp on the pGraph to see whether or not the resulting graph has no other counter-examples for the invariant inv (i.e. |
| Uses of Partition in synoptic.algorithms.graph |
|---|
| Fields in synoptic.algorithms.graph declared as Partition | |
|---|---|
private Partition |
PartitionSplit.newPartition
Partition that will be used for storing eventsToSplitOut once this operation commits. |
private Partition |
PartitionMultiSplit.partition
|
private Partition |
PartitionSplit.partitionToSplit
Partition that will be split by this operation. |
(package private) Partition |
PartitionMerge.removed
|
(package private) Partition |
PartitionMerge.retained
|
private Partition |
PartitionMultiMerge.retainedPartition
|
| Fields in synoptic.algorithms.graph with type parameters of type Partition | |
|---|---|
private java.util.ArrayList<Partition> |
PartitionMultiMerge.partitionsToMerge
|
| Methods in synoptic.algorithms.graph that return Partition | |
|---|---|
Partition |
PartitionSplit.getPartition()
Gets the partition to split. |
Partition |
PartitionMultiSplit.getPartition()
Gets the partition that will be split. |
Partition |
PartitionMerge.getRemoved()
Get the partition that was removed from the graph. |
| Methods in synoptic.algorithms.graph with parameters of type Partition | |
|---|---|
static PartitionSplit |
PartitionSplit.newSplitWithAllEvents(Partition partition)
Create a partition split that would split all messages of partition into a separate node. |
| Constructors in synoptic.algorithms.graph with parameters of type Partition | |
|---|---|
PartitionMerge(Partition retained,
Partition removed)
Creates a PartitionMerge. |
|
PartitionMultiMerge(Partition partition,
java.util.ArrayList<Partition> partitionsToMerge)
Creates a partition multi merge. |
|
PartitionSplit(Partition partitionToSplit)
Creates a partition split. |
|
PartitionSplit(Partition partitionToSplit,
Partition newPartitionArg)
Creates a partition split. |
| Constructor parameters in synoptic.algorithms.graph with type arguments of type Partition | |
|---|---|
PartitionMultiMerge(Partition partition,
java.util.ArrayList<Partition> partitionsToMerge)
Creates a partition multi merge. |
| Uses of Partition in synoptic.gui |
|---|
| Fields in synoptic.gui with type parameters of type Partition | |
|---|---|
(package private) edu.uci.ics.jung.graph.DirectedGraph<INode<Partition>,ITransition<Partition>> |
JungGui.jGraph
The visual representation of pGraph, displayed by the Applet. |
(package private) edu.uci.ics.jung.graph.DirectedGraph<INode<Partition>,ITransition<Partition>> |
JungGui.jGraph
The visual representation of pGraph, displayed by the Applet. |
(package private) edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> |
JungGui.layout
The layout used to display the graph. |
(package private) edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> |
JungGui.layout
The layout used to display the graph. |
(package private) java.util.LinkedHashMap<Partition,java.lang.Integer> |
JungGui.newPartitions
Partitions that were created in the latest refinement step are mapped to the number of LogEvents they contain. |
(package private) java.util.LinkedHashMap<Partition,java.lang.Integer> |
JungGui.oldPartitions
Partitions that are known from the prior refinement step are mapped to the number of LogEvents they contain. |
(package private) edu.uci.ics.jung.visualization.VisualizationViewer<INode<Partition>,ITransition<Partition>> |
JungGui.vizViewer
the visual component and renderer for the graph |
(package private) edu.uci.ics.jung.visualization.VisualizationViewer<INode<Partition>,ITransition<Partition>> |
JungGui.vizViewer
the visual component and renderer for the graph |
| Methods in synoptic.gui that return types with arguments of type Partition | |
|---|---|
edu.uci.ics.jung.graph.DirectedGraph<INode<Partition>,ITransition<Partition>> |
JungGui.getJGraph()
|
edu.uci.ics.jung.graph.DirectedGraph<INode<Partition>,ITransition<Partition>> |
JungGui.getJGraph()
|
| Method parameters in synoptic.gui with type arguments of type Partition | |
|---|---|
protected void |
GuiVertex.paintShapeForVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
INode<Partition> v,
java.awt.Shape shape)
|
protected void |
GuiVertex.paintShapeForVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
INode<Partition> v,
java.awt.Shape shape)
|
protected void |
GuiVertex.paintShapeForVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
INode<Partition> v,
java.awt.Shape shape)
|
void |
GuiVertex.paintVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> layout,
INode<Partition> v)
|
void |
GuiVertex.paintVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> layout,
INode<Partition> v)
|
void |
GuiVertex.paintVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> layout,
INode<Partition> v)
|
void |
GuiVertex.paintVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> layout,
INode<Partition> v)
|
void |
GuiVertex.paintVertex(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
edu.uci.ics.jung.algorithms.layout.Layout<INode<Partition>,ITransition<Partition>> layout,
INode<Partition> v)
|
private void |
JungGui.refine(java.util.List<RelationPath<Partition>> counterExampleTraces)
|
protected boolean |
GuiVertex.vertexHit(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
java.awt.Shape s)
|
protected boolean |
GuiVertex.vertexHit(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc,
java.awt.Shape s)
|
| Constructor parameters in synoptic.gui with type arguments of type Partition | |
|---|---|
ModalMousePlugin(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc)
|
|
ModalMousePlugin(edu.uci.ics.jung.visualization.RenderContext<INode<Partition>,ITransition<Partition>> rc)
|
| Uses of Partition in synoptic.model |
|---|
| Fields in synoptic.model declared as Partition | |
|---|---|
private Partition |
MessageToPartitionIterator.next
|
private Partition |
LogEvent.parent
The partition that contains this log event. |
| Fields in synoptic.model with type parameters of type Partition | |
|---|---|
private java.util.LinkedHashSet<Partition> |
PartitionGraph.partitions
holds all partitions in this graph |
private java.util.Set<Partition> |
MessageToPartitionIterator.seen
|
java.util.LinkedHashMap<Partition,java.util.Set<Partition>> |
PartitionGraph.transitionCache
a cache of inter-partition transitions |
java.util.LinkedHashMap<Partition,java.util.Set<Partition>> |
PartitionGraph.transitionCache
a cache of inter-partition transitions |
| Methods in synoptic.model that return Partition | |
|---|---|
private Partition |
MessageToPartitionIterator.getNext()
|
Partition |
Partition.getParent()
|
Partition |
LogEvent.getParent()
|
Partition |
MessageToPartitionIterator.next()
|
Partition |
PartitionGraph.partitionFromMessage(LogEvent message)
|
| Methods in synoptic.model that return types with arguments of type Partition | |
|---|---|
java.util.Set<Partition> |
PartitionGraph.getAdjacentNodes(Partition pNode)
Returns a set of partitions that are adjacent to pNode. |
private java.util.Set<Partition> |
PartitionGraph.getAllRelationsLogEventPartitions(java.util.LinkedHashMap<java.lang.String,java.util.Set<LogEvent>> map)
|
java.util.Comparator<Partition> |
Partition.getComparator()
|
java.util.Set<Partition> |
PartitionGraph.getInitialNodes()
|
java.util.Set<Partition> |
PartitionGraph.getInitialNodes(java.lang.String relation)
|
java.util.Set<Partition> |
PartitionGraph.getNodes()
|
private java.util.Set<Partition> |
PartitionGraph.getRelationLogEventPartitions(java.lang.String relation,
java.util.LinkedHashMap<java.lang.String,java.util.Set<LogEvent>> map)
|
java.util.Set<Partition> |
PartitionGraph.getTerminalNodes()
|
java.util.Set<Partition> |
PartitionGraph.getTerminalNodes(java.lang.String relation)
|
ITransition<Partition> |
Partition.getTransition(Partition iNode,
java.lang.String action)
|
java.util.List<Transition<Partition>> |
Partition.getTransitions()
This method returns the set of transitions. |
IIterableIterator<Transition<Partition>> |
Partition.getTransitionsIterator()
Transitions between partitions are not stored but generated on demand using this iterator |
IIterableIterator<Transition<Partition>> |
Partition.getTransitionsIterator(java.lang.String act)
Generate Edges on the fly. |
java.util.List<WeightedTransition<Partition>> |
Partition.getWeightedTransitions()
|
java.util.Iterator<Partition> |
MessageToPartitionIterator.iterator()
|
| Methods in synoptic.model with parameters of type Partition | |
|---|---|
void |
PartitionGraph.add(Partition node)
|
void |
Partition.addTransition(Partition dest,
java.lang.String relation)
|
void |
PartitionGraph.clearNodeAdjacentsCache(Partition node)
|
java.util.Set<Partition> |
PartitionGraph.getAdjacentNodes(Partition pNode)
Returns a set of partitions that are adjacent to pNode. |
PartitionSplit |
Partition.getCandidateDivisionBasedOnIncoming(Partition previous,
java.lang.String relation)
Split the partition according to an incoming transition from previous labeled with relation . |
ITransition<Partition> |
Partition.getTransition(Partition iNode,
java.lang.String action)
|
void |
PartitionGraph.mergeAdjacentsCache(Partition from,
Partition to)
|
void |
PartitionGraph.remove(Partition node)
|
void |
Partition.setParent(Partition parent)
|
void |
LogEvent.setParent(Partition parent)
|
void |
PartitionGraph.tagInitial(Partition initialNode,
java.lang.String relation)
|
void |
PartitionGraph.tagTerminal(Partition terminalNode,
java.lang.String relation)
|
| Method parameters in synoptic.model with type arguments of type Partition | |
|---|---|
private static boolean |
Partition.fulfillsStrong(LogEvent event,
ITransition<Partition> trans)
Whether or not there exists a transition t' emanating from an event that (1) matches the relation of another (inter-partition) transition t, and (2) matches the destination partition of t |
PartitionSplit |
Partition.getCandidateDivisionBasedOnOutgoing(ITransition<Partition> trans)
Split the events according to the presence of an outgoing transition trans (the source in trans is ignored here). |
| Uses of Partition in synoptic.model.interfaces |
|---|
| Methods in synoptic.model.interfaces that return Partition | |
|---|---|
Partition |
INode.getParent()
Get the parent partition of this node. |
| Methods in synoptic.model.interfaces with parameters of type Partition | |
|---|---|
void |
INode.setParent(Partition parent)
Set the parent partition of this node. |
|
||||||||||
| PREV NEXT | FRAMES NO FRAMES |


Preparation time
30 mins to 1 hour
Cooking time
30 mins to 1 hour
Serves
Serves 4
Preheat the oven to 180C/350F/Gas 4.
For the pork chops, place everything but the pork chops into a large bowl and whisk to combine. Add the pork chops and stir to coat. Set aside to marinate for 30 minutes in a cool place.
Heat a griddle pan until hot. Place the pork chops into the pan and griddle on each side for two minutes. Transfer the chops to a baking sheet and place in the oven for 10-15 minutes, or until completely cooked through.
Meanwhile, for the Savoy cabbage poriyal, heat a frying pan until hot and add the oil, mustard seeds, curry leaves and ginger. Stir until the mustard seeds pop, taking care as it may spit.
Add the cabbage, turmeric and salt and fry gently for 10-15 minutes, or until the cabbage is wilted. Remove from the heat and stir in the freshly grated coconut, coriander leaves and lemon juice.
For the salad, heat a frying pan until hot, add the oil and garlic and fry until light golden-brown. Add the coriander seeds and red chilli.
Add the chopped apples and fry gently for a few minutes to colour lightly. Add the mushrooms and fry until lightly browned. Add the lemon juice and cider vinegar and season with salt and sugar, to taste. Remove from the heat and stir in the chopped parsley.
To serve, place the cabbage poriyal in the centre of four serving plates and top with a pork chop. Scatter the apple and porcini salad around the plate and drizzle over the liquid left in the pan. Sprinkle the mixed cress on top of the salad and serve immediately.


--- title: Theory of Juice featuredImage: /foo.jpg date: 2000-02-02 link: https://theory.com/juice/ ---
juice appeal


The Tragedy of MacBeth
by William Shakespeare
Act 3, Scene 4
Additional Information
- Year Published: 1607
- Language: English
- Country of Origin: England
- Source: Richard Grant White, ed. The Complete Works of William Shakespeare (New York: Sully and Kleinteich)
-
Readability:
- Flesch–Kincaid Level: 11.0
- Word Count: 1,353
- Genre: Tragedy
- Keywords: betrayal, envy, murder, power, revenge, tragedy
- ✎ Cite This
Downloads
SCENE. The same. Hall in the palace.
(A banquet prepared. Enter MACBETH, LADY MACBETH, ROSS, LENNOX, Lords, and Attendants)
MACBETH
You know your own degrees; sit down: at first
And last the hearty welcome.
Lords
Thanks to your majesty.
MACBETH
Ourself will mingle with society,
And play the humble host.
Our hostess keeps her state, but in best time
We will require her welcome.
LADY MACBETH
Pronounce it for me, sir, to all our friends;
For my heart speaks they are welcome.
(First Murderer appears at the door)
MACBETH
See, they encounter thee with their hearts' thanks.
Both sides are even: here I'll sit i' the midst:
Be large in mirth; anon we'll drink a measure
The table round.
(Approaching the door)
There's blood on thy face.
First Murderer
'Tis Banquo's then.
MACBETH
'Tis better thee without than he within.
Is he dispatch'd?
First Murderer
My lord, his throat is cut; that I did for him.
MACBETH
Thou art the best o' the cut-throats: yet he's good
That did the like for Fleance: if thou didst it,
Thou art the nonpareil.
First Murderer
Most royal sir,
Fleance is 'scaped.
MACBETH
Then comes my fit again: I had else been perfect,
Whole as the marble, founded as the rock,
As broad and general as the casing air:
But now I am cabin'd, cribb'd, confined, bound in
To saucy doubts and fears. But Banquo's safe?
First Murderer
Ay, my good lord: safe in a ditch he bides,
With twenty trenched gashes on his head;
The least a death to nature.
MACBETH
Thanks for that:
There the grown serpent lies; the worm that's fled
Hath nature that in time will venom breed,
No teeth for the present. Get thee gone: to-morrow
We'll hear, ourselves, again.
(Exit Murderer)
LADY MACBETH
My royal lord,
You do not give the cheer: the feast is sold
That is not often vouch'd, while 'tis a-making,
'Tis given with welcome: to feed were best at home;
From thence the sauce to meat is ceremony;
Meeting were bare without it.
MACBETH
Sweet remembrancer!
Now, good digestion wait on appetite,
And health on both!
LENNOX
May't please your highness sit.
(The GHOST OF BANQUO enters, and sits in MACBETH's place)
MACBETH
Here had we now our country's honour roof'd,
Were the graced person of our Banquo present;
Who may I rather challenge for unkindness
Than pity for mischance!
ROSS
His absence, sir,
Lays blame upon his promise. Please't your highness
To grace us with your royal company.
MACBETH
The table's full.
LENNOX
Here is a place reserved, sir.
MACBETH
Where?
LENNOX
Here, my good lord. What is't that moves your highness?
MACBETH
Which of you have done this?
Lords
What, my good lord?
MACBETH
Thou canst not say I did it: never shake
Thy gory locks at me.
ROSS
Gentlemen, rise: his highness is not well.
 Are you a man?
MACBETH
Ay, and a bold one, that dare look on that
Which might appall the devil.
LADY MACBETH
O proper stuff!
This is the very painting of your fear:
This is the air-drawn dagger which, you said,
Led you to Duncan. O, these flaws and starts,
Impostors to true fear, would well become
A woman's story at a winter's fire,
Authorized by her grandam. Shame itself!
Why do you make such faces? When all's done,
You look but on a stool.
MACBETH
Prithee, see there! behold! look! lo! how say you?
Why, what care I? If thou canst nod, speak too.
If charnel-houses and our graves must send
Those that we bury back, our monuments
Shall be the maws of kites.
(GHOST OF BANQUO vanishes)
LADY MACBETH
What, quite unmann'd in folly?
MACBETH
If I stand here, I saw him.
LADY MACBETH
Fie, for shame!
MACBETH
Blood hath been shed ere now, i' the olden time,
Ere human statute purged the gentle weal;
Ay, and since too, murders have been perform'd
Too terrible for the ear: the times have been,
That, when the brains were out, the man would die,
And there an end; but now they rise again,
With twenty mortal murders on their crowns,
And push us from our stools: this is more strange
Than such a murder is.
LADY MACBETH
My worthy lord,
Your noble friends do lack you.
MACBETH
I do forget.
Do not muse at me, my most worthy friends,
I have a strange infirmity, which is nothing
To those that know me. Come, love and health to all;
Then I'll sit down. Give me some wine; fill full.
I drink to the general joy o' the whole table,
And to our dear friend Banquo, whom we miss;
Would he were here! to all, and him, we thirst,
And all to all.
Lords
Our duties, and the pledge.
(Re-enter GHOST OF BANQUO)
MACBETH
Avaunt! and quit my sight! let the earth hide thee!
Thy bones are marrowless, thy blood is cold;
Thou hast no speculation in those eyes
Which thou dost glare with!
LADY MACBETH
Think of this, good peers,
But as a thing of custom: 'tis no other;
Only it spoils the pleasure of the time.
MACBETH
What man dare, I dare:
Approach thou like the rugged Russian bear,
The arm'd rhinoceros, or the Hyrcan tiger;
Take any shape but that, and my firm nerves
Shall never tremble: or be alive again,
And dare me to the desert with thy sword;
If trembling I inhabit then, protest me
The baby of a girl. Hence, horrible shadow!
Unreal mockery, hence!
(GHOST OF BANQUO vanishes)
Why, so: being gone,
I am a man again.
LADY MACBETH
You have displaced the mirth, broke the good meeting,
With most admired disorder.
MACBETH
Can such things be,
And overcome us like a summer's cloud,
Without our special wonder? You make me strange
Even to the disposition that I owe,
When now I think you can behold such sights,
And keep the natural ruby of your cheeks,
When mine is blanched with fear.
ROSS
What sights, my lord?
LADY MACBETH
I pray you, speak not; he grows worse and worse;
Question enrages him. At once, good night:
Stand not upon the order of your going,
But go at once.
LENNOX
Good night; and better health
Attend his majesty!
LADY MACBETH
A kind good night to all!
(Exeunt all but MACBETH and LADY MACBETH)
MACBETH
It will have blood; they say, blood will have blood:
Stones have been known to move and trees to speak;
Augurs and understood relations have
By magot-pies and choughs and rooks brought forth
The secret'st man of blood. What is the night?
LADY MACBETH
Almost at odds with morning, which is which.
MACBETH
How say'st thou, that Macduff denies his person
At our great bidding?
LADY MACBETH
Did you send to him, sir?
MACBETH
I hear it by the way; but I will send:
There's not a one of them but in his house
I keep a servant fee'd. I will to-morrow,
And betimes I will, to the weird sisters:
More shall they speak; for now I am bent to know,
By the worst means, the worst. For mine own good,
All causes shall give way: I am in blood
Stepp'd in so far that, should I wade no more,
Returning were as tedious as go o'er:
Strange things I have in head, that will to hand;
Which must be acted ere they may be scann'd.
LADY MACBETH
You lack the season of all natures, sleep.
MACBETH
Come, we'll to sleep. My strange and self-abuse
Is the initiate fear that wants hard use:
We are yet but young in deed.
(Exeunt)


Amazon EMR InstanceGroupConfig CloudWatchAlarmDefinition
The CloudWatchAlarmDefinition
property specifies
the conditions that trigger an automatic scaling activity. CloudWatchAlarmDefinition
is a subproperty of the Amazon EMR
InstanceGroupConfig ScalingTrigger property type.
Syntax
JSON
{ "ComparisonOperator" :
String
, "Dimensions" : [MetricDimension
, ... ], "EvaluationPeriods" :Integer
, "MetricName" :String
, "Namespace" :String
, "Period" :Integer
, "Statistic" :String
, "Threshold" :Double
, "Unit" :String
}
YAML
ComparisonOperator:
String
Dimensions: -MetricDimension
EvaluationPeriods:Integer
MetricName:String
Namespace:String
Period:Integer
Statistic:String
Threshold:Double
Unit:String
Properties
ComparisonOperator
-
Determines how the metric specified by
MetricName
is compared to the value specified byThreshold
.Valid values:
GREATER_THAN_OR_EQUAL
,GREATER_THAN
,LESS_THAN
, orLESS_THAN_OR_EQUAL
.Required: Yes
Type: String
Dimensions
-
A list of CloudWatch metric dimensions.
Required: No
Type: List of Amazon EMR InstanceGroupConfig MetricDimension
EvaluationPeriods
-
The number of periods, expressed in seconds using the
Period
property, during which the alarm condition must exist before the alarm triggers automatic scaling activity. The default value is 1.Required: No
Type: Integer
MetricName
-
The name of the CloudWatch metric that is watched to determine an alarm condition.
Required: Yes
Type: String
Namespace
-
The namespace for the CloudWatch metric. The default is
AWS/ElasticMapReduce
.Required: No
Type: String
Period
-
The period, in seconds, over which the statistic for applying the metric associated with the alarm is applied. You specify the statistic in the
Statistic
property. CloudWatch metrics for Amazon EMR are emitted every five minutes (300 seconds). If you specify a CloudWatch metric for Amazon EMR, specify 300.Required: Yes
Type: Integer
Statistic
-
The statistic to apply to the metric associated with the alarm. The default is
AVERAGE
.Valid values:
SAMPLE_COUNT
,AVERAGE
,SUM
,MINIMUM
, andMAXIMUM
.Required: No
Type: String
Threshold
-
The value against which the specified statistic is compared.
Required: Yes
Type: Double
Unit
-
The unit of measure associated with the CloudWatch metric being watched. Specify the unit specified in the CloudWatch metric.
For more information, see CloudWatchAlarmDefinition in the Amazon EMR API Reference.
Required: No
Type: String


I’ve been going a bit mental 😵 in regards to fonts recently, and I think web-fonts or font compression for use on the web is essential for anyone serious about web development.
WOFF2 or Web Open Font Format 2 is the second iteration of the web-font format. The WOFF formats compress your desired TTF and OTF fonts to be efficiently used on the web.
WOFF uses zlib for compression while WOFF2 uses Brotli for compression.
WOFF grants a >40% reduction to file size vs traditional TTF while WOFF2 grants a >30% reduction to file size vs WOFF.
Support:
WOFF
WOFF2
Grab the source from here and install it. Note that compilation requires GCC. Afterwards, you get two command woff2_compress and woff2_decompress. Both commands take one argument each; use woff2_compress to compress a TTF or OTF file to WOFF2 or use woff2_decompress to decompress a WOFF2 file to its original format (OTF/TTF).
woff2_compress font.otf
woff2_decompress font.woff2
And there you have it. Simple and effective. Happy coding! 🙌🎉
Special thanks to Diomari Madulara 🙇 for the image.


{% extends 'base.html'%} {% import 'macros.html' as macro%} {% block styles%} {{ super() }} {% endblock %} {% block content %}
Ubudehe refers to the long-standing Rwandan practice and culture of collective action and mutual support to solve problems within a community, according to a recent academic research paper.
Information is the major thing in everybody's personal life. Ubudehe helps Rwandan citizen to access things basing on thier living style, in every aspect of life. It also helps people from knowing that they have equal rights where someone can not be in charge of something above his/her acapabilities.
Ubudehe was launched into Rwandan life it was as way to better involve communities in their development by setting up participatory problem solving mechanisms. The program was seen as a way to strengthen democratic processes and good governance through greater community involvement in decision making. Ubudehe creates opportunities for people at all levels of society, especially the village level, to interact with one another, share ideas, create institutions and make decisions for their collective development.
This government statment has been a way of facilitating everybody according to his/her right and the limitation of his capabilities. Yes.It is way of poverty reduction where the government support people with lower living founds by offering and giving them what they need (eg: Gira inka Munyarwanda) according to their ubudehe categories. Others, are able to access other government founds like asking for loan or gain a scholarship for thier studies.


Cuban Transplant Program Recognized
by RHCThe Cuban Minister of Public Health, José Ángel Portal, held a meeting with directors of the Ibero-American Network/Council of Donation and Transplantation, who held in Havana its nineteenth meeting, reports the Public Health Ministry website.
Havana, Cuba.- The meeting took place in the context of the Donation of Organs, Tissue and Transplantation Day whose main activities Cuba hosted this year.
Donation and transplantation is an indicator of the quality of health care, and in this sense, Cuba shows favorable results, acknowledged the Network´s president, Beatriz Domínguez.
José Ángel Portal explained that amid the economic limitations that the country is going through, the National Transplant Program continues to be strengthened, and he stressed that its success is also based on compliance with ethical principles.
Representatives of almost 40 countries and from the Pan American and World Health Organizations (PAHO/WHO) gathered in Havana for the Ibero-American Network/Council of Donation and Transplantation meeting.
Dr. Antonio Enamorado, the national coordinator of the Transplant Program of the Cuban Ministry of Public Health, told the Cuban News Agency that the island has a donation rate between 13 and 14 per million inhabitants, making it one of the first countries in Latin America.
Solid-organ transplants began in Cuba in 1972 with kidney transplantation.
Enamorado added that the program has never stopped and that in the mid-1980s the first heart transplant was carried out, and they were followed by liver, bone marrow and cornea transplants, among others. (RHC)


Price
1 SQUA
= 0,1 BNB
MarketCap
5.000.000 SQUA
Enter the wallet data.
Address
*Check your wallet data before sending.
Save
Create
Whitelist
Publish
Whitelist
Inssue
Token
How to buy?
How to negotiate?
Confirm your address
Address
0X0000000000000
Confirm
Cancel


|
| def | __init__ (self, target_coder, size, textfile, max_length, num_utt) |
| | BatchDispenser constructor. More...
|
| |
| def | split (self, num_utt) |
| | take a number of utterances from the batchdispenser to make a new one More...
|
| |
|
def | get_pair (self) |
| | get the next input-target pai
|
| |
|
def | num_labels (self) |
| | the number of output labels
|
| |
|
def | max_input_length (self) |
| | the maximal sequence length of the features
|
| |
|
def | max_target_length (self) |
| | the maximal length of the targets
|
| |
|
def | num_utt (self) |
| | The number of utterances in the given data.
|
| |
|
def | pos (self) |
| | the current position in the data
|
| |
|
def | pos (self, pos) |
| | setter for the current position in the data
|
| |
| def | __init__ (self, size) |
| | batchDispenser constructor More...
|
| |
| def | get_batch (self, pos=None) |
| | Get a batch of features and targets. More...
|
| |
| def | split (self, num_utt) |
| | take a number of utterances from the batchdispenser to make a new one More...
|
| |
|
def | get_pair (self) |
| | get the next input-target pai
|
| |
| def | num_batches (self) |
| | The number of batches in the given data. More...
|
| |
|
def | num_utt (self) |
| | The number of utterances in the given data.
|
| |
|
def | num_labels (self) |
| | the number of output labels
|
| |
|
def | max_input_length (self) |
| | the maximal sequence length of the features
|
| |
|
def | max_target_length (self) |
| | the maximal length of the targets
|
| |
|
def | pos (self) |
| | the current position in the data
|
| |
|
def | pos (self, pos) |
| | setter for the current position in the data
|
| |
a batch dispenser, used for language model training


Résumé
— I'm the most successful person ever to run for the presidency, by far. Nobody's ever been more successful than me. I'm the most successful person ever to run. Ross Perot isn't successful like me. Romney ― I have a Gucci store that's worth more than Romney. Sorry losers and haters, but my IQ is one of the highest ― and you all know it!
Experience
Recent
-
2020
Trump lost to Democrat Joseph Biden.
-
2019
Financial Times included Trump in its list of 50 people who "have shaped the face of decade"
-
2018
18 Republican congressmen nominated his for the 2019 Nobel Peace Prize for his efforts to address the Korean issue. -
2017
Became 45th president of the United States
-
2016
Won election race with 77 votes more than Clinton
-
2015
Became the most important Republican nominating for presidential election run
Back then
-
2009
Changed my mind and became Republican again
-
2005
no grades, certificates and other bureaucracy, but program offered courses in real estate, asset management entrepreneurship, and wealth creation. 98% students gave positive reviews while studying, however some of these ungrateful gringos filed lawsuits against Trump University after the course. I had to pay $25 million to settle that... -
2002
Acquired the former Hotel Delmonico, which was renovated and reopened in 2004 as the Trump Park Avenue. I sure do like my surname!
-
2001
Completed Trump World Tower and joined the Democratic Party
-
1999
Started buying golf courses. They are very cheap, I have 18 of them now in USA and abroad! Also switched to the Reform Party that year
-
1997
Me and the other investors sold our shares for $1.8 billion and that was then the biggest residential sale in the history of New York City -
1996
Acquired the Bank of Manhattan Trust Building, which was a vacant seventy-one story skyscraper on Wall Street. After an extensive renovation, the high-rise was renamed the Trump Building
-
1994
Refurbished the Gulf and Western Building on Columbus Circle, turned it into a 44-story luxury property known as Trump International Hotel and Tower
-
1989 - 1992
Ran a second hand airline called Trump Shuttle. What a waste of money, I had to sell it, now it is American Airlines Shuttle, btw
-
1989 - 1990
Learned about Tour de France and decided to hold my very own Tour de Trump. Is America not great enough for that cycling competition?
-
1988
Acquired the Plaza Hotel in Manhattan for $407 million, invested $50 million to restore the building and boosted it from three-star to four-star hotel (I called it "the Mona Lisa" and sold it for a lot of cash in 1995)
-
1987
Registered as a Republican
-
1985
and turned it into a private club.You can join if you pay $200K initiation fee (and there is another annual fee for members, it is very expensive to be rich). That year I also opened a casino called Trump Castle. My wife Ivana became a manager, because she is another Trump! -
1983
I purchased New Jersey Generals, an American football team. I changed team's play schedule and filed an antitrust lawsuit against United States Football League, so NJG are not doing so good now, but back then they were great!
-
1980
Started developing the Trump Tower skyscraper in Manhattan, I payed a crew of undocumented Polish workers to demolish the historic Bonwit Teller store, including art deco features. All this to make architectural critic Paul Goldberger say in 1983 that the tower's atrium is "the most pleasant interior public space to be completed in New York in some years". At the same time I also started a repair job on the Wollman Rink in Central Park and completed the work in three months for $1.95 million, which was $775,000 less than the initial budget! -
1978
Purchased a 50 percent stake in the derelict Commodore Hotel and turned it into the Grand Hyatt Hotel in 2 years of remodeling
-
1971
Was promoted to president of the company and renamed it The Trump Organization
-
1968
Began my career at my father's real estate development company, Elizabeth Trump & Son
PERSONAL LIFE
-
2006
Melania gained United States citizenship and gave birth to our son, Barron
-
2005
Married her
-
1998
Met my future third wife, Melania Knauss
-
1999
Divorced Marla
-
1993
Married Marla and had a daughter, we named her Tiffany
-
1992
Started affair with Marla Maples, so I had to divorce. God knows I love nice women, I love them all!
-
1984
Birth of Eric Trump
-
1982
Birth of Ivanka Trump
-
1977
My first son is born. I called him Donald, of course!
-
1977
Married Czech model Ivana Zelníčková
MEDIA CAREER
-
2019
Was awarded Worst Actor and Worst Screen Combo at Golden Raspberry Awards for parts in "Death of a Nation" and "Fahrenheit 11/9"
-
2015
Published a book "Crippled America: How to Make America Great Again"
-
2011
Published a book "Time to Get Tough: Making America #1 Again" in coauthorship with Wynton Hall, Peter Schweizer and Meredith McIver
-
2011
Published a book "Midas Touch: Why Some Entrepreneurs Get Rich – And Why Most Don't" in coauthorship with Robert Kiyosaki
-
2011
Published a book "Trump Tower" in coauthorship with Jeffrey Robinson
-
2009
Published a book "Think Like a Champion: An Informal Education in Business and Life" in coauthorship with Meredith McIver
-
2008
Published a book "Never Give Up: How I Turned My Biggest Challenges into Success" in coauthorship with Meredith McIver
-
2007
Published a book "Think Big and Kick Ass" in coauthorship with Bill Zanker
-
2007
Received a star on the Hollywood Walk of Fame for being producer of Miss Universe pageant
-
2006
Published a book "Why We Want You to Be Rich" in coauthorship with Meredith McIver and Robert Kiyosaki
-
2006
Published a book "How to Build a Fortune: Your Plan for Success From the World's Most Famous Businessman"
-
2006
Published a book "The Best Real Estate Advice I Ever Received: 100 Top Experts Share Their Strategies"
-
2006
Published a book "Trump 101: The Way to Success" in coauthorship with Meredith McIver
-
2005
Published a book "The Best Golf Advice I Ever Received"
-
2005
Performed a song with Megan Mullally at the 57th Primetime Emmy Awards
-
2004 - 2008
Ran short-form talk radio program "Trumped!" (one to two minutes on weekdays)
-
2004
Published a book "Trump: How to Get Rich" in coauthorship with Meredith McIver
-
2004
Published a book "The Way to the Top: The Best Business Advice I Ever Received"
-
2004
Published a book "Think Like a Billionaire: Everything You Need to Know About Success, Real Estate, and Life" in coauthorship with Meredith McIver
-
2003 - 2015
Produced NBC reality shows "The Apprentice" and "The Celebrity Apprentice"
-
2000
Published a book "Trump: The America We Deserve" in coauthorship with Dave Shiflett
-
1997
Published a book "Trump: The Art of the Comeback" in coauthorship with Kate Bohner
-
1991
Was awarded Worst Supporting Actor at Golden Raspberry Awards for a part in "Ghosts Can't Do It"
-
1990
Published a book "Trump: Surviving at the Top" in coauthorship with Charles Leerhsen
-
1987
Published a book "Trump: The Art of the Deal" in coauthorship with Tony Shwartz
Languages
Skills
Character
Likes😃
Dislikes😞
Wants🥺
Education
-
2011
-
1966Transferred to the Wharton School of the University of Pennsylvania and graduated in May 1968 with a B.S. in economic
-
1964Started studying in Fordham University
-
1959Enrolled in the New York Military Academy, a private boarding school, after my parents discovered I made frequent trips into Manhattan without their permission


--- layout: post title: Books That Influenced Me date: 2015-01-26 categories: tags: books author: remyhonig excerpt: Books I've read and have influenced me --- {% for book in site.data.books limit:10 %}
{{ book.description }}


{% extends "layout.html" %} {% block page_title %} Money Claims Prototype {% endblock %} {% block content %} ALPHA This is a new service – your feedback will help us to improve it. Back Make a suggestion You can now make a suggestion to reach a common ground with them. What do you want to suggest? You can now make a suggestion to resolve this dispute. Offer some money How much money do you offer? Non-monetary remedy - eg complete the work, fix the problem etc. Your suggestion Add conditions (optional) {% endblock %}
ALPHA This is a new service – your feedback will help us to improve it.
You can now make a suggestion to reach a common ground with them.


{% extends 'base_email_cta.html' %} {% block title %}Your great.gov.uk account{% endblock %} {% block cta_url %}{{ activate_url }}{% endblock %} {% block synopsis %}
You recently signed up for an Exporting is Great account.
Verify your email address by clicking the button below.
You will then be able to sign in and access Exporting is Great services.
{% endblock %} {% block cta_label %}Verify your email address{% endblock %}


Actually, I'm putting edit 6 up here: D'oh! My test packet was sending out byte and emon only handles int and thinks a single byte is garbage nondata. That was bloody well everything that was going wrong, right from the start. 'Trap for young players', I guess Dave'd say.
----------------------------
I am presumably missing something obvious, but I can't figure it out.
My hardware is currently, just at the proof-of-concept stage, one raspberry pi and 2 jeenodes. One jeenode, powered by a jee AA board, is running the jeelib/DIJN/test2 sketch and is blipping once a second with the current light level. The other jeenode is connected to the RPi using an FT232RL board (running at 3V3 logic and 5V on the VCC pin, into the 3V3 regulator).
I have loaded the Rpi-node with the rf12-demo firmware from the R12Pi. Both nodes are configured with 868 MHz and group 97, with the central node being 15 and the lightnode being 17.
As you can see, the central node is quite happily receiving the data pings. I swept my hand over the LDR once or twice to prove it was getting real data. Next issue is getting the data into emoncms. That's where the snag is.
My Rpi is running (over the SD card and a 16G Lexar USB key -- it'll get a proper HDD eventually) the "Raspberry Pi + Harddrive + Emoncms", with only a few mods. Because my data collection node is on ttyUSB0 rather than ttyAMA0, I changed all the occurrences of that in /var/www:
I can't find anywhere else on the system that mentions ttyAMA, apart from /dev/xconsole.
And yet despite many reboots and hair-tearing I am not getting a working data feed, even though I must be *so* *close*.
What am I missing?
Edit: Okay, i forgot something I wanted to try. The jeenode is now hooked straight to the GPIO pins:
Still no data. So presumably I'm just making a beginner's mistake somewhere and it's actually much easier than all the stuff I've been trying.
Edit2: Oh, _result_. Using the raspberry Pi rfm12 to pi module/thingy on the webinterface if I change the node ID of the central node, the jeenode actually does change its node number. This confirms that emoncms is actually talking to the jeenode just fine. In fact if I'm listening to ttyAMA0 on an ssh I can see emoncms pushing the 15i/17i/etc commands to the node. Now why is that input not updating....
Edit3: Aha -- apparently, even if you have a local setup, you have to fill in the "forward data to remote server" section. With <IP_ADDRESS>. I still don't seem to be getting my node 17 feed coming through, though.
Edit4: Just to be safe, I tried forwarding to my emoncms account instead of local. No joy. AFAICT the code used in my test2 sketch uses the same dataformat as an emontx, except with just one value that means little:
rf12_sendNow(0, &value, 1);
vs:
rf12_sendNow(0, &emontx, sizeof emontx);
I am gathering from more and more doc reading that data should just magically appear in Inputs, right? nobody seems to be telling anyone how to get it there, when using an rfm12pi setup.
Edit5: In desperation, I went with just the oemgateway setup now, and following the troubleshooting steps, I get what I had been suspecting for a while now:
2014-01-14 12:37:24,961 INFO Serial RX: 17 152
2014-01-14 12:37:24,965 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:25,993 INFO Serial RX: 17 152
2014-01-14 12:37:25,996 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:27,024 INFO Serial RX: 17 152
2014-01-14 12:37:27,028 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:28,056 INFO Serial RX: 17 152
2014-01-14 12:37:28,059 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:29,087 INFO Serial RX: 17 152
So, my data packets are the wrong format. Argh! if I'd figured that out sooner that would've saved me some testing there...
Initial setup not working. --FIXED--
Submitted by Jasper on Mon, 13/01/2014 - 21:49Actually, I'm putting edit 6 up here: D'oh! My test packet was sending out byte and emon only handles int and thinks a single byte is garbage nondata. That was bloody well everything that was going wrong, right from the start. 'Trap for young players', I guess Dave'd say.
----------------------------
I am presumably missing something obvious, but I can't figure it out.
My hardware is currently, just at the proof-of-concept stage, one raspberry pi and 2 jeenodes. One jeenode, powered by a jee AA board, is running the jeelib/DIJN/test2 sketch and is blipping once a second with the current light level. The other jeenode is connected to the RPi using an FT232RL board (running at 3V3 logic and 5V on the VCC pin, into the 3V3 regulator).
I have loaded the Rpi-node with the rf12-demo firmware from the R12Pi. Both nodes are configured with 868 MHz and group 97, with the central node being 15 and the lightnode being 17.
As you can see, the central node is quite happily receiving the data pings. I swept my hand over the LDR once or twice to prove it was getting real data. Next issue is getting the data into emoncms. That's where the snag is.
My Rpi is running (over the SD card and a 16G Lexar USB key -- it'll get a proper HDD eventually) the "Raspberry Pi + Harddrive + Emoncms", with only a few mods. Because my data collection node is on ttyUSB0 rather than ttyAMA0, I changed all the occurrences of that in /var/www:
I can't find anywhere else on the system that mentions ttyAMA, apart from /dev/xconsole.
And yet despite many reboots and hair-tearing I am not getting a working data feed, even though I must be *so* *close*.
What am I missing?
Edit: Okay, i forgot something I wanted to try. The jeenode is now hooked straight to the GPIO pins:
Still no data. So presumably I'm just making a beginner's mistake somewhere and it's actually much easier than all the stuff I've been trying.
Edit2: Oh, _result_. Using the raspberry Pi rfm12 to pi module/thingy on the webinterface if I change the node ID of the central node, the jeenode actually does change its node number. This confirms that emoncms is actually talking to the jeenode just fine. In fact if I'm listening to ttyAMA0 on an ssh I can see emoncms pushing the 15i/17i/etc commands to the node. Now why is that input not updating....
Edit3: Aha -- apparently, even if you have a local setup, you have to fill in the "forward data to remote server" section. With <IP_ADDRESS>. I still don't seem to be getting my node 17 feed coming through, though.
Edit4: Just to be safe, I tried forwarding to my emoncms account instead of local. No joy. AFAICT the code used in my test2 sketch uses the same dataformat as an emontx, except with just one value that means little:
rf12_sendNow(0, &value, 1);
vs:
rf12_sendNow(0, &emontx, sizeof emontx);
I am gathering from more and more doc reading that data should just magically appear in Inputs, right? nobody seems to be telling anyone how to get it there, when using an rfm12pi setup.
Edit5: In desperation, I went with just the oemgateway setup now, and following the troubleshooting steps, I get what I had been suspecting for a while now:
2014-01-14 12:37:24,961 INFO Serial RX: 17 152
2014-01-14 12:37:24,965 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:25,993 INFO Serial RX: 17 152
2014-01-14 12:37:25,996 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:27,024 INFO Serial RX: 17 152
2014-01-14 12:37:27,028 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:28,056 INFO Serial RX: 17 152
2014-01-14 12:37:28,059 WARNING Misformed RX frame: ['17', '152']
2014-01-14 12:37:29,087 INFO Serial RX: 17 152
So, my data packets are the wrong format. Argh! if I'd figured that out sooner that would've saved me some testing there...


Anand Sivasankar
General Manager
Lucien Sanders
Animation Specialist | Team Lead
Pavan Teja Bhatta
Web Developer Specialist | Team Lead
Tontrakun Chaimongkol
Marketing Specialist | Team Lead
Somya Tomar
Data Analyst | Team Lead
Anil Simon
Web Developer
Arun Davis
Marketing Analyst
Bonnie Teng
Digital Marketing Analyst
David Vera
Systems Administrator
Dipak Basnet
Graphic Designer
Irantzu Sangroniz
Visual Designer
Jane Balashova
Graphic Designer
Kinjal Patel
Web Developer
Rashmi Venex Dsouza
Blockchain Technology Analyst
Ronald Dacayanan
Marketing Analyst
Vijay Kumar Saraf
Systems Administrator


The examples that are shipped as part of the Mercurial.Net repository requires LINQPad to run, a free tool made by the author of C# 40 in a Nutshell, a O'Reilly book about C# 4.0, LINQ and various other topics.
Note that you need LINQPad version 4.27.1 or higher, as the scripts here rely on a relatively new feature where the script can discover its location on disk. This is used so that the scripts work against the repository of Mercurial.Net automatically.
Ensure that you load up the solution file in Visual Studio 2010, and do a full rebuild for the Debug target before testing any of the examples. They rely on the binary produced as part of the build output.
The examples numbered 100 and upwards are excercising the GUI client, TortoiseHg.


Pre-Processing XY Data from Experimental Methods.
Pre-Processing XY Data from Experimental Methods.
Allen’s Interval Algebra for Archaeologists.
A Web tool for converting CAs with dating information to relative time intervals as RDF.
An R package for Smith’s Mean Measure of Divergence (MMD), with a graphical user interface, facilities for trait selection and graphical representations.
Estimate probabilities of find numbers per period.
R package for the analysis of the fragmentation of archeological objects.
Python script for analyzing data sets of archaeological artifacts containing only Boolean and categorical variables.
Working with map data in R.
R script that implements a means for statistically assessing the degree of co-occurrence between classes within a dataset.
R-script for conducting and evaluating bootstrapped correspondence analyses.
Script for calculating Brainerd-Robinson coefficients based on tabular count or percent data. This script also estimates the probability that a given difference between two samples is the product of sampling error.
R Script for Seriation Using Correspondence Analysis.
R package to help interpreting Correspondence Analysis’ results.
R Package for contingency tables seriation via Correspondence Analysis.
A bookdown powered manual for the small scale cultural heritage organization looking to leverage various chi techniques for their own collections.
Tools for chronological uncertainty propagation.
An Approximate Bayesian Computation Framework for inferring patterns of cultural transmission from frequency data.
A simulation tool to estimate the rate of success that surveys possessing user-specific characteristics have in identifying archaeological sites (or any groups of clouds of objects), given specific parameters of survey area, survey methods, and site properties.
Simple Principal Components Analysis (PCA) and Correspondence Analysis (CA) based on the Singular Value Decomposition (SVD). This package provides S4 classes and methods to compute, extract, summarize and visualize results of multivariate data analysis. It also includes methods for partial bootstrap validation.
Application (in LibreOffice Calc) for serializing a graphic matrix from counting tables. The application makes it possible to obtain either a serograph or a graph of the PVI matrograph type (visualization of the differences in independence from the percentages of independence values) which does not favor the vision of the variables over that of the lines and more suitable for non-chronological treatments.
Code for Geostatistics in ethnographic contexts.
Script for conducting K-means cluster analysis using R. This script provides output designed to help the user select an appropriate cluster solution.
Codes for performing kriging for ethnographic and archaeological data.
Tool for calculating the largest empty circles and estimation of archaeological sites theoretically to be expected in region of interest, an implementation of the method published by Andreas Zimmermann and Karl Peter Wendt (2003).
Moran’s I and Getis-Ord G* Analysis.
Script for calculating mean ceramic dates based on tabular data. This script also estimates sampling error using a bootstrapping procedure.
R script for analyzing presence/absence data in irregularly distributed archaeological survey units.
Implements Near Presence Cluster Analysis, a statistical method for identifying spatial clustering within presence / absence data observed in irregularly distributed areal observation units.
A function for retrieving metrics for resistance-resilience from rcarbon permTest objects.
An R package implementing functions to perform spatio-temporal paleoclimate reconstruction from tree-rings using the CAR (Correlation Adjusted corRelation) approach of Zuber and Strimmer.
Pure Locational Clustering.
Point Pattern Analysis.
A package to analyze data used to determine whether samples from multiple sources can be separated, to predict the sources of samples from unknown sources, and to evaluation the validity of those predictions. Sample data can include both quantitative and qualitative data. The package includes functions for creating an analysis file from multiple files and exploratory data analysis, as well as multivariate statistical methods to determine source separation, predict sources of unknown samples, and evaluate the validity of the predictions (principal components, classification trees, and random forests).
R Library for Quantitative Analysis in Archaeology.
Finding quantum in archaeological data using cosine quantogram and related statistical methods.
An R package to facilitate the use of Murail et al.’s (1999) approach of sex estimation in past populations.
Functions for analysing and visualizing rates of evolution.
R package that provides the infrastructure for ordering objects with an implementation of several seriation/sequencing/ordination techniques to reorder matrices, dissimilarity matrices, and dendrograms (see below for a full list). Also provides (optimally) reordered heatmaps, color images and clustering visualizations like dissimilarity plots, and visual assessment of cluster tendency plots (VAT and iVAT).
Algorithms, implementations, manuscripts, and test cases for iterative deterministic frequency seriation done by agglomeration.
This R package contains exactly one function, that calculates the “sum of individual weighted means” according to a methodology that is quite common among archaeologists and was first published in 1988 by Elisabeth Fentress and Philip Perkins.
Statistical pattern recognition and dating using archaeological artefacts assemblages.
Analysis of spatial gradients in radiocarbon dates.
Analysis, Seriation and Visualization of Archaeological Count Data.
Tools for Quantitative Archaeology - in R.
Tool for Online Seriation and Correspondence Analysis.
Tutorials on quantitative archaeology.
Unconstrained Clustering.
R implementation of the Uniform Probability Density Analysis approach


My Tech Stack
This is a non-exhaustive and constantly changing list of tools, ecosystems, and software I like to use.
I value stable, boring technology more than fadtech.
Infrastructure
- Git (keeps my notes, configs and this website synced up)
- Linux (server, desktop, embedded)
- Unix (technically unix-likes, FreeBSD and MacOS)
- gitea/gitlab-ce (two self-hosted git repositories I like for different reasons. gitlab-ce is better for onprem, gitea for small teams)
- Docker (and podman)
- Virtualization (QEMU and Virtualbox mainly, have had some fun with FreeBSD bhyve and jails in the past)
- ZFS and BTRFS
- Ansible (automation)
- Bash (automation and general scripting fun)
- Javascript (nodejs and currently using deno a lot)
- Server hardening and best practices(learning container security practices since that's the way the industry has shifted)
- Vue (and derivatives like Nuxt)
SaaS I like Using
- Twilio (Telephony is a black box most of the time, much easier with Twilio)
- Sendgrid (Also by Twilio, but much better/cheaper for newsletters than Constant Contact and other email marketing "tools"
- AWS (When self-hosting is not an option)
- Netlify(It's fast, although I also like Deno Deploy)
Fun Stuff
- Hugo(and I guess, other SSGs) I started with Jekyll way back when, moved to Hugo for simplicity.
- A-Frame (for building AR/XR experiences and generally having a good time)
- Twine (Great for telling stories, surprisingly good as a presentation tool as well)
- Judo (the sport, not a flavor-of-day frontend)